BACKGROUND The gut microbiota plays crucial roles in the development of non-alcoholic steatohepatitis (NASH). However, the precise mechanisms by which alterations of the gut microbiota and its metabolism contributing to the pathogenesis of NASH are not yet fully elucidated. METHODS Mice were fed with a recently reported new class of high-fat diet (HFD), steatohepatitis-inducing HFD (STHD)-01 ...

Non-alcoholic steatohepatitis (NASH) is a disease of emerging identity and importance. It is frequently associated with obesity, especially visceral fat, and is intimately related to fatty liver and markers of the insulin resistance syndrome. Both the prevalence and the severity of liver steatosis are related to body mass index, waist circumference, hyperinsulinaemia, hypertriglyceridaemia and ...

Nonalcoholic steatohepatitis (NASH) is an underdiagnosed liver disease and is the main cause of persistent elevated serum liver enzymes among the general population. Here, we report the case of a 32-year-old obese man who was diagnosed as a case of chronic hepatitis caused by HBV infection. He was treated with Lamivudine for two years. Though his HBV DNA load became negative, he had persistentl...

Non-alcoholic fatty liver disease (NAFLD) has become the most common cause of chronic worldwide. Understanding pathological and molecular hallmarks from its first description to definitions entities, classifications phenotypes is crucial for both appropriate clinical management research in this complex disease. We provide an overview through almost two hundred years beginnings as a nebulous ent...

Non-alcoholic steatohepatitis (NASH) is characterized by liver steatosis and inflammation. Currently, the underlying mechanisms leading to hepatic inflammation are not fully understood and consequently, therapeutic options are poor. Non-alcoholic steatohepatitis (NASH) and atherosclerosis share the same etiology whereby macrophages play a key role in disease progression. Macrophage function can...

Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic disorders worldwide. In an aggressive type, non-alcoholic steatohepatitis (NASH) might lead to cirrhosis and hepatocellular carcinoma progression. Currently, there no certified drug applied treat NASH. Human studies have demonstrated beneficial effects probiotics supplementation in NAFLD. Due lack appropr...

Introduction Chronic liver inflammation leads to liver cirrhosis, which is the 12th leading cause of death in the US (1), accounting for 32,000 deaths in the US and more than 1 million deaths each year worldwide (2). Chronic pathologic processes include viral infection, alcoholic liver disease, nonalcoholic steatohepatitis (NASH), and autoimmune diseases. Depending on the type of underlying liv...

A high-fat "Western-style" diet (HFWD) promotes obesity-related conditions including non-alcoholic steatohepatitis (NASH), the histologic manifestation of non-alcoholic fatty liver disease (NAFLD). In addition to high saturated fat and processed carbohydrates, the typical HFWD is deficient in calcium. Calcium-deficiency is an independent risk factor for many conditions associated with the Weste...

Obeticholic acid (OCA) or 6-alpha-ethyl-chenodeoxycholic is a semisynthetic modified bile derivative that acts on the farnesoid X receptor (FXR) as an agonist with higher potency than acid. The FXR nuclear highly expressed in liver and small intestine regulates acid, cholesterol, glucose metabolism, inflammation, apoptosis. group of receptors currently under investigation for their potential ro...

The mechanisms underlying the progression of simple steatosis to steatohepatitis are yet to be elucidated. To identify the proteins involved in the development of liver tissue inflammation, we performed comparative proteomic analysis of non-alcoholic steatohepatitis (NASH). Mice fed a methionine and choline deficient diet (MCD) developed hepatic steatosis characterized by increased free fatty a...